Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Reversible airway obstruction in children with ataxia telangiectasia
Yackov Berkun
,
Daphna Vilozni
, Yonit Levi
, Sheron Borik
, Dalia Waldman
,
Raz Somech
,
Andreea Nissenkorn
,
Ori Efrati
*
*
Corresponding author for this work
Pediatrics
Sheba Medical Center at Tel Hashomer
Tel Aviv University
Research output
:
Contribution to journal
›
Article
›
peer-review
24
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Reversible airway obstruction in children with ataxia telangiectasia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Age-matched
14%
Airway Obstruction
100%
Anti-asthma
14%
Asthma
14%
Asthma Symptoms
14%
Asthma Treatment
14%
Ataxia Telangiectasia
100%
Bronchodilator
28%
Clinical Characteristics
14%
Clinical Response
14%
Clinical Symptoms
14%
Early Treatment
14%
FEF25-75
28%
Forced Expiratory Volume in 1 Second (FEV1)
42%
Healthy children
28%
Israeli
14%
Lung Disease
14%
Lung Function
14%
Lung Function Tests
14%
Medical Data
14%
Nutritional Condition
14%
Obstructive Lung Disease
14%
Peak Flow
42%
Peak Flow Reduction
14%
Pulmonary Involvement
14%
Rise Time
28%
Short Lifetime
14%
Spirometry
28%
Spirometry Data
14%
Time to Peak
28%
Medicine and Dentistry
Airway Obstruction
100%
Asthma
28%
Ataxia Telangiectasia
100%
Bronchodilating Agent
28%
Deterioration
14%
Forced Expiratory Volume
14%
Lifespan
14%
Lung
28%
Obstructive Lung Disease
14%
Peak Expiratory Flow
57%
Silo-Filler's Disease
14%
Spirometry
42%
Nursing and Health Professions
Airway Obstruction
100%
Asthma
28%
Ataxia Telangiectasia
100%
Bronchodilator
28%
Deterioration
14%
Forced Expiratory Volume
14%
Lung Disease
14%
Obstructive Lung Disease
14%
Peak Expiratory Flow
57%
Spirometry
42%
Immunology and Microbiology
Airway
100%
Asthma
28%
Ataxia Telangiectasia
100%
Bronchodilator
28%
Forced Expiratory Volume
14%
Lifespan
14%
Peak Expiratory Flow
57%
Pharmacology, Toxicology and Pharmaceutical Science
Airway Obstruction
100%
Asthma
28%
Ataxia Telangiectasia
100%
Bronchodilating Agent
28%
Chronic Obstructive Lung Disease
14%
Deterioration
14%
Lung Disease
14%